PsychU

Virtual Event - Pathophysiology Of Agitation Associated With Alzheimer’s Dementia (AD) - The Potential Role Of The Norepinephrine, Serotonin & Dopamine (NSD) Neurotransmitter Systems
2024-08-30 18:00 - 19:00 (America/Los_Angeles)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU members in California.
In this presentation, topics of discussion are:

Loss of behavior regulation in agitation associated with AD
Monoamine systems in agitation associated with AD pathophysiology

Norepinephrine
Serotonin
Dopamine

Featuring

Lea Grinberg Korczyn, MD, PhD
Full Professor & Senior Associate Consultant-Pathology at Mayo Clinic Florida

John Awad, MD (OPDC)
Senior Medical Science Liaison

Speaker Lea Grinberg, MD, PhD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker John Awad, MD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Psychotherapeutic Approaches in PTSD Treatment
2024-08-22 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE

Clinical guidelines recommend both pharmacologic and non-pharmacological interventions in the treatment of post-traumatic stress disorder (PTSD)1. This presentation will highlight these interventions in addition to exploring the benefits of combined pharmacological and non-pharmacologic treatments. Objectives for this webinar include: a review of PTSD diagnostic criteria; common psychotherapies utilized in PTSD; a discussion of the challenges associated with engaging patients in psychotherapy; and the benefits of combined pharmacologic and non-pharmacologic treatments.

Join us for an informative webinar moderated by Haneefa Rakeeb DNP, PMHNP-BC, RN alongside esteemed speaker Christiian Storm Credle, PsyD.

References:

U.S. Department of Veterans Affairs. 2023. www.healthquality.va.gov/guidelines/MH/ptsd/VA-DoD-CPG-PTSD-Full-CPG.pdf

Featured Speakers

Christiian Storm Credle, PsyD (he/him/his)
Director of Behavioral Health at Mazzoni Medical Center in Philadelphia, PA

Haneefa Rakeeb, DNP, PMHNP-BC, AFN-BC
Medical Science Liaison, Otsuka Pharmaceutical Development & Commercialization, Inc.

More

Haneefa has been a nurse for over 10 years and is a certified psychiatric mental nurse practitioner. She is board certified as an advanced forensic nurse through the ANCC and is specialized as a sexual assault nurse examiner since 2013. She earned her doctorate degree in nursing practice in 2021 from Wilkes University, with a focus on the relationship between PTSD and sexual assault patients.

Christiian Storm Credle, PsyD, is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.

Haneefa Rakeeb, DNP, PMHNP-BC, RN is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc.

Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
June 2024 US.CORP.X.24.00197

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - PTSD: Epidemiology, Trauma Types, Risk Factors, Diagnosis, Clinical Presentation & Course
2024-08-21 12:00 - 13:00 (America/Los_Angeles)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This slide deck will examine the prevalence, incidence, and demographics of post-traumatic stress disorder (PTSD), explore trauma types, review important screening and diagnostic tools, plus delve into the complexities encountered during the initial presentation and subsequent assessment of PTSD. Please note: This virtual live event is restricted to PsychU members in Alaska, Washington, Oregon, and California.

Featuring

Elika Hefazi, PharmD, BCPP
Medical Science Liaison

Simon Kim, PharmD
Medical Science Liaison

Elika Hefazi, PharmD, BCPP (OPDC) and Simon Kim, PharmD (OPDC) are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

The Agitation In Alzheimer’s Screener For Caregivers (AASC™): How Caregivers Can Use This New Screener To Recognize The Breadth Of Agitation Symptoms & Facilitate Conversations With Healthcare Professionals
2024-08-01 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
As a follow-up to the previous webinar, “An Introduction to the AASCTM,” this webinar will re-ground on the current landscape of Alzheimer’s dementia (AD) and the negative impact agitation in Alzheimer’s dementia (AAD) has on both caregivers and patients. Additionally, it will introduce guidance on how caregivers should use the AASCTM to support patients. During this session, presenters will provide a didactic overview and engage in role-playing scenarios to illustrate how community caregivers can use the AASCTM to facilitate a conversation with their health care provider (HCP).

Featuring

Marc E. Agronin, MD
Agitation Section Advisor; President of the American Association for Geriatric Psychiatry (AAGP); Senior Vice President for Behavioral Health and Chief Medical Office for the Memory and Research Center at MIND Institute; Affiliate Associate Professor of Psychiatry and Neurology at the University of Miami Miller School of Medicine

Carrie Shaw, MD
CEO & Founder of Embodied Labs

Katie Sulkowski, PharmD
Medical Science Liaison

Speakers Dr. Marc E. Agronin and Carrie Shaw are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Katie Sulkowski, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Improving Quality Of Life, Functioning & Well-being In Individuals Living With Bipolar Disorder
2024-07-25 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Bipolar disorder is a lifelong, chronic mental health disorder characterized by extreme shifts in mood that can have a profound negative effect on daily functioning, cognition, and quality of life for individuals living with the disorder.1 During this webinar, guest speaker Dr. Martha Sajatovic, and Medical Science Liaison, Taylor Ochalek, will address why quality of life may be compromised in individuals with bipolar disorder and review the utility of measurement-based tools. Dr. Sajatovic will then discuss potential advantages of implementing both pharmacological and psychosocial interventions to improve quality of life, functioning and well-being.

References:
1. Bonnín CDM, et al. Improving Functioning, Quality of Life, and Well-being in Patients with Bipolar Disorder. Int J Neuropsychopharmacol. 2019 Aug 1;22(8):467-477.

Featuring

Martha Sajatovic, MD
Psychiatrist, Director Neurological and Behavioral Outcomes Center, University Hospital Cleveland Medical Center and Professor, Case Western Reserve University School of Medicine

More

Martha Sajatovic, MD holds the Willard Brown Chair in Neurological Outcomes at University Hospitals Cleveland Medical Center (UH CMC) and the Rocco L. Motto Professorship in Child & Adolescent Psychiatry. Dr. Sajatovic directs the Neurological and Behavioral Outcomes Center at UHCMC/Case Western Reserve University. She has subspecialty certification in Behavioral Neurology & Neuropsychiatry. Dr. Sajatovic is a Professor of Psychiatry and Neurology at Case Western Reserve University School of Medicine (CWRU) in Cleveland, Ohio. Dr. Sajatovic is a researcher, educator, and clinician who has devoted herself to studying and treating traditionally, hard-to-treat populations with central nervous system disorders. Dr. Sajatovic’s research interests have focused on neuropsychiatric outcomes of brain disorders across the life-span, including epilepsy, stroke, Alzheimer’s disease, and other types of dementia and Parkinson’s disease. She has authored or co-authored over 250 peer-reviewed publications and has published over 40 book chapters or books on neuropsychiatric topics. Dr. Sajatovic has been a recipient of the Exemplary Psychiatrist Award bestowed by the National Alliance for the Mentally Ill (NAMI), was a Depression and Bipolar Support Alliance (DBSA) Gerald Klerman Investigator Award winner in 2006 and 2016, and in 2018 received the Rebecca Goldberg Kaufman American Epilepsy Society (AES) Clinical Award in Ethical Neuropsychiatry.

Taylor Ochalek, PhD
Medical Science Liaison

Speaker Martha Sajatovic, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Taylor Ochalek is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Pseudobulbar Affect (PBA) In Patients With Traumatic Brain Injury (TBI)
2024-07-17 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Join us as Michelle Lavagnino and Dr. Heidi Fusco discuss an overview of Pseudobulbar Affect (PBA) in Traumatic Brain Injury (TBI) patients. This webinar will discuss the prevalence and burden of TBI patients suffering from PBA and the importance of diagnosing in several different practice settings.

Featuring

Heidi Fusco, PM&R
Assistant Professor, Department of Rehabilitation Medicine at NYU Grossman School of Medicine; Medical Director, Brain Injury Unit, Queens Nassau Nursing and Rehabilitation; Assistant Director, Traumatic Brain Injury Program

Michelle Lavagnino, DrPH(c)
Medical Science Liaison, Long-term Care

Dr. Heidi Fusco is a paid consultant of Otsuka Pharmaceutical Development & Commercialization. (OPDC)Michelle Lavagnino is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Practical Application Of Wellness Strategies For Individuals In Underserved Communities With Major Depressive Disorder (MDD) & Post-Traumatic Stress Disorder (PTSD)
2024-07-11 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Approximately 50 million United States adults are living with a mental illness, with 21 million having depression and 13 million with post-traumatic stress disorder.1-4 Minority individuals are among these prevalence statistics but are less likely to receive mental health care.5 In commemorating National Minority Mental Health Month, join us on this webinar moderated by Miranda Fisher, PhD and featuring Ifeanyi M. Olele, DO, MBA, MS, where they will discuss the prevalence and impact of mental illness within the underserved communities, address the clinical presentation of MDD & PTSD present in this population, and share practical wellness approaches to integrate and support the recovery journey for these individuals.

References:

Mental Health of America. Quick Facts and Statistics About Mental Health. Quick Facts and Statistics About Mental Health | Mental Health America (mhanational.org). Accessed May 2024
Lehavot K et al. Am J Pre Med. 2018;54(1), e1-e9.
US Census Bureau. (2022). National Population by Characteristics: 2020-2022. Retrieved from https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html. (Data on file).
U.S. Department of Veterans Affairs (VA). How Common is PTSD in Adults? How Common is PTSD in Adults? – PTSD: National Center for PTSD (va.gov) . Accessed May 2024
Depression and Bipolar Support Alliance. Statistics About Disparities in Mental Health Care. Statistics About Disparities in Mental Health Care – Depression and Bipolar Support Alliance (dbsalliance.org). Accessed May 2024

Featuring

Ifeanyi Olele, DO, MBA, MS
Psychiatrist & CEO at Genesis Psychiatric Solutions, Washington DC & Genesis TMS and Wellness, Fairfax VA

More

Ifeanyi M. Olele is a psychiatrist & CEO of Genesis Psychiatric Solutions in Washington D.C. He is a Board-Certified psychiatrist and completed his undergraduate studies in Psychobiology at the University of California Los-Angeles (UCLA). Dr. Olele received a medical degree from Philadelphia College of Osteopathic Medicine (PCOM) along with an MBA in Health Services Administration from St. Joseph’s University in Philadelphia. He also earned a Master of Science degree in Medical Science from Hampton University in Hampton, Virginia. Upon completion of medical school, Dr. Olele completed his psychiatry residency and served as Chief Resident in Larkin Community Hospital in Miami, Florida. Dr. Olele received training on maternal mental health at the Seleni Institute and cognitive behavior therapy at the Beck Institute.

Miranda Fisher, PhD
Medical Science Liaison

Speaker Ifeanyi Olele, DO, MBA, MS is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Miranda Fisher, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Major Depressive Disorder In Chronic Kidney Disease
2024-06-20 18:00 - 20:00 (America/New_York) | Eleven, 1150 Smallman Street, Pittsburgh, PA, 15222, United States
Home

Events

About This Event

TEST VLE
This is a PsychU & NephU Joint Live Event for PsychU members in the Pittsburgh, PA area.
In this presentation, the objectives are to:

Overview of Major Depressive Disorder (MDD) and Chronic Kidney Disease (CKD)/End Stage Renal Disease (ESRD).
Discuss the high prevalence of depression in patients with CKD.
Discuss how overlap of symptomatology between MDD and CKD makes diagnosing depression in the setting of CKD challenging.
Discuss the association of MDD with poor outcomes in CKD.
Discuss potential risk factors and mechanism of MDD in CKD.
Discuss the cycle between MDD and ESRD.
Address challenges in MDD management considerations in CKD patients.

Venue

Featuring

Jessica Kanai, PharmD (OPDC)
Medical Science Liaison

More

Jessica is a nephrology Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc.

Katie Sulkowski, PharmD
Medical Science Liaison

Speakers Katie Sulkowski, PharmD and Jessica Kanai, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Antipsychotic Treatment Options In Schizophrenia
2024-06-20 18:00 - 19:30 (America/New_York) | Angeline, 581 Delaware St, Buffalo, NY, 14202, United States
Home

Events

About This Event

TEST VLE
This is a Live Event for PsychU members in the Buffalo, NY area.

In this presentation, the objectives are to:

Review evolution of antipsychotic treatments
Discuss definitions of adherence and possible reasons for nonadherence
Compare evidence supporting oral and long-acting injectable antipsychotics
Discuss potential communication strategies for patients and providers

Venue

Featuring

Carl DeFranco, MSN, PMHNP-BC
Psychiatric Mental Health Nurse Practitioner

More

Carl DeFranco is a board certified Psychiatric Mental Health Nurse Practitioner through the American Nurses Credentialing Center (ANCC).
He has obtained his Professional Registered Nurse degree from Niagara County Community College, Bachelor of Science in Nursing from Daemen University, and Master of Science in Nursing from D’Youville University. As a registered nurse he has worked in treatment areas such as hospice, renal transplant, Burn Treatment Unit, and Medical Intensive Care Unit at our local Level 1 Trauma Center in Buffalo, NY. As a nurse practitioner, he has worked in outpatient community mental health, psychiatric homecare, and Assertive Community Treatment.

Sara A. Spencer, PharmD, MS, BCGP
Medical Science Liaison

Speaker Carl DeFranco, MSN, PMHNP-BC is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Sara A. Spencer, PharmD, MS, BCGP is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Ask A Digital Navigator: Adopting Technology To Improve Mental Health
2024-06-20 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
As digital mental health tools are becoming an integral part of our healthcare landscape, there is a need to integrate them in our clinical practice. Dr. Maria Perez will facilitate this discussion about the role of digital navigators. Our experts, Noy Alon and Sarah Perret, will present on the challenges of implementing digital mental health tools into clinical practice, define the role of the digital navigator, and discuss the role of digital navigators in the implementation of technology into health care.

Featuring

Noy Alon, BS
Medical Student, Icahn School of Medicine at Mount Sinai, New York, NY

More

Noy Alon, BS was formerly the digital literacy director at the Digital Psychiatry Lab, Beth Israel Deaconess Medical Center, and led the team’s digital literacy curriculum development and community outreach. She also worked on app evaluation and was in charge of updating the largest database of mental health applications, known as the M-health Index and Navigation Database (MIND). Noy helped co-lead several digital navigator trainings and has trained over 100 behavioral health clinicians, volunteers, and community members in implementing digital health solutions.

Sarah Perret, MS, BS
Associate Editor, npj Women’s Health, Boston, MA

More

Sarah Perret served as the digital education director at the Digital Psychiatry Lab, Beth Israel Deaconess Medical Center, and led the team’s digital navigator training. She also worked on app evaluation and with perinatal women in the digital clinic.

Maria Perez, PharmD, AAHIVP
Medical Science Liaison – Digital Therapeutics

Speakers Noy Alon, BS and Sarah Perret, MS, BS are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Maria Perez, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Webinar Pre-Polling

Please fill out this survey before the webinar!

Pre polling survey for 6/20 webinar

How familiar are you with a Digital Navigator?

Not at all familiar

Slightly familiar

Moderately familiar

Extremely familiar
How often do you incorporate Digital Mental Health Tools in your practice?

Not at all

Infrequently

Sometimes

Most of the time

Always

Δ

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Unmet Needs In Agitation Associated With Alzheimer's Dementia (AAD)
2024-06-06 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU members in Delaware, Maryland, New Jersey, Pennsylvania, and West Virginia.
This evidence-based review highlights important aspects of agitation associated with Alzheimer’s Dementia (AAD) for better understanding of prevalence and challenges in diagnosis and explore the potential pathobiological correlations in AAD. Describes the clinical and humanistic burden and discusses current guidelines for nonpharmacological and pharmacological treatments of this complex and prominent complication of an already devastating disease. It underlines unmet needs for FDA-approved pharmaceutical treatments for agitation to improve care and quality of life for patients suffering from AAD.

Featuring

E. Jeffrey Greenberg, MD
Neurologist at Princeton & Rutgers Neurology, P.A., Co-Founder of Advanced Clinical Institute

More

Dr. Jeffrey Greenberg, a native of Philadelphia, joined Princeton & Rutgers Neurology in 2003. He received his Bachelor’s degree in English from Cornell University and his medical degree from Drexel University, College of Medicine. He completed his Neurology residency at the Albert Einstein College of Medicine in New York, serving as Chief Resident in his final year. He subsequently completed an EMG/Neuromuscular fellowship at Albert Einstein. He is Board Certified in Neurology by the American Board of Psychiatry and Neurology and also Board Certified by the American Associate of Neuromuscular and Electrodiagnostic Medicine.

Dr. Greenberg now focuses his practice on Parkinson’s Disease, Dementia, Multiple Sclerosis, and Neuromuscular Disease. Additionally, he has experience as a Principle Investigator for Alzheimer’s disease clinical trials and remains involved in the field.

Becky Wong, PharmD, MBA
Medical Science Director

Speaker E. Jeffrey Greenberg, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Becky Wong, PharmD, MBA is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Care Coordination For Adult Patients With SMI - From Inpatient To Outpatient
2024-05-22 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Live Event for PsychU members in Delaware, Maryland, New Jersey, New York, Pennsylvania, and West Virginia.
In this presentation, topics of discussion are:

Program introduction
Clinical course of serious mental illness (SMI)
Risk factors for relapse/recurrence
Discussion of coordination of care and discharge planning
Hypothetical profile of a patient with SMI

Featuring

Salvatore G. Savatta, MD
Chair of Psychiatry, Trinitas Regional Medical Center, Elizabeth, NJ

More

Dr. Salvatore G. Savatta received his Bachelor of Arts degree in Economics from New York University, graduated from New York University School of Medicine in 2001 and completed his M.S. in Biostatistics Clinical Research Methods at Columbia University’s Mailman School of Public Health in 2005. Dr. Savatta has previously served as Director of Inpatient Psychiatry at New York Methodist Hospital, Medical Director of TMS Centers of America and both Deputy Chair and Interim Chair of Psychiatry at Trinitas Regional Medical Center. He presently serves as Chair of Psychiatry at Trinitas and has done so since May of 2020.
Dr. Savatta completed his Psychiatry Residency at St. Vincent’s Catholic Medical Center and completed a Public Service Psychiatry Fellowship and a Forensic Psychiatry Fellowship at the University of Pittsburgh Medical Center – Western Psychiatric Institute and Clinic. Dr. Savatta is Board Certified in both Adult Psychiatry and Forensic Psychiatry.
He has tailored his clinical practice to focus on “difficult to treat” depression, and often includes the implementation of Neuromodulation techniques such as TMS, Esketamine, and Electroconvulsive Therapy (ECT) when clinically appropriate.

Jehan Marino, PharmD, BCPP
Medical Science Director

Becky Wong, PharmD, MBA
Medical Science Director

Speaker Salvatore G. Savatta, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speakers Jehan Marino, PharmD, BCPP and Becky Wong, PharmD, MBA are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Combating Self-Stigma In Persons With Serious Mental Illness (SMI) With Narrative Enhancement & Cognitive Therapy (NECT)
2024-05-22 12:00 - 12:30 (America/New_York)
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Self-stigma refers to the negative attitudes, including internalized shame, that people with mental illness have about their condition.1 Many interventions are available to address self-stigma in the serious mental illness (SMI) population, and one of them is Narrative Enhancement and Cognitive Therapy (NECT). NECT is a manualized group-based psychosocial intervention that is directed towards helping people who have been labeled with a psychiatric diagnosis recover their sense of value and decrease internalized/self-stigma.2
Come and join us for this webinar, moderated by Sara Spencer, PharmD, MS, BCGP and featuring NECT founder, Philip Yanos, Ph.D., who will share the impact of internalized stigma on SMI individuals as well as the NECT methodology and provide a practical case vignette for implementation and application of this innovative therapy intervention into clinical practice.
Reference:

Stigma, Prejudice, and Discrimination Against People with Mental Illness. American Psychiatric Association. Psychiatry.org – Stigma, Prejudice, and Discrimination Against People with Mental Illness. Accessed: March 2024.
Narrative Enhancement and Cognitive Therapy. NECT Global. NECT Global

Featuring

Philip T. Yanos, PhD
Professor, Department of Psychology, John Jay College of Criminal Justice, City University of New York

More

Philip is a professor in the Psychology Department at John Jay College and The Graduate Center. A clinical psychologist, he received his Ph.D. in from St. John’s University in 1999 and completed a post-doctoral fellowship in mental health services research at Rutgers University in 2001, and has been faculty at John Jay since 2006. He is an internationally recognized expert in mental health stigma, author of the book “Written-Off: Mental Health Stigma and the Loss of Human Potential” (Cambridge University Press, 2018), associate editor of the journal “Stigma and Health,” and the author of over 130 peer-reviewed publications. He has been awarded the John Jay College Scholarly Excellence Award 5 times since 2009.

Sara A. Spencer, PharmD, MS, BCGP
Medical Science Liaison

Speaker Sara Spencer, PharmD, MS, BCGP is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Home

Events

Importance Of Adherence On Individuals With Bipolar Disorder
2024-05-16 18:30 - 20:30 (America/New_York) | Craft Kitchen + Bar, 93 Mill Plain Rd, Danbury, CT, 06811, United States
Home

Events

About This Event

TEST VLE
This is a Live Event for PsychU members in Connecticut.
Treatment non-adherence is a dilemma in bipolar disorder and is one of the leading challenges in providing effective treatments for people diagnosed with BP I disorder. During our discussion today, the speaker will discuss and define some of these challenges and provide the latest information on treatment-related determinants of adherence. We will also discuss some of the factors important to adherence.

Venue

Featuring

Joseph Goldberg, MD
Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai

More

Joseph F. Goldberg, MD is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. He attended college at the University of Chicago, graduate school in neuroscience at the University of Illinois, and medical school at Northwestern University. He completed his residency and chief residency in psychiatry, and fellowship in psychopharmacology, at the Payne Whitney Clinic, New York Presbyterian Hospital, where he later served on the faculty and was site Principal Investigator at Weill-Cornell Medical Center for the NIMH STEP-BD program. He has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology, most recently “Managing the Side Effects of Psychotropic Medications, 2nd edition” published in 2019 by American Psychiatric Publishing, and the forthcoming “Practical Psychopharmacology” by Cambridge University Press. He serves on the Board of Directors for the American Society of Clinical Psychopharmacology and is on the editorial boards for a number of peer-reviewed journals. His research has been awarded funding from NARSAD, NIMH, the Stanley Foundation, and the American Foundation for Suicide Prevention. Dr. Goldberg is a Distinguished Fellow of the American Psychiatric Association and has been listed for many years in Best Doctors in America and Castle Connolly’s “America’s Top Doctors.”

Jehan Marino, PharmD, BCPP
Medical Science Director

Yasmin Togun, PhD
Medical Science Liaison

More

Dr. Yasmin Togun is a CNS Medical Science Liaison at Otsuka, covering Connecticut, Massachusetts. Rhode Island, Vermont, New Hampshire, and Maine. She is a Licensed Clinical Psychologist with a focus on Pediatric Psychology and Health Service Psychology. Prior to joining Otsuka, she practiced as an Attending Psychologist on the Psychiatry Consultation Liaison Service at Boston Children’s Hospital and a Clinical Instructor of Psychology at Harvard Medical School.

Speaker Joseph Goldberg, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speakers Jehan Marino, PharmD, BCPP and Yasmin Togun, PhD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Exploring Post-Traumatic Stress Disorder: Pathophysiology
2024-05-16 12:00 - 12:30 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Although there may be many etiologies, Post-Traumatic Stress Disorder (PTSD) is a dynamic disorder that involves fluctuations between contrasting forms of emotional dysregulation.1 This webinar will provide a high-level overview of the pathophysiology of PTSD, including discussion of the potential role of monoamine neurotransmitter systems involved in emotional regulation and fear response in the amygdala.

References:
1. Yehuda R, et al. Nat Rev Dis Primers. 2015;1:15057.

Featuring

Steven Stoner, PharmD
Associate Dean for Student Affairs/Clinical Professor, University of Missouri-Kansas City School of Pharmacy

More

Steven Stoner, PharmD, BCPP, is Board Certified in Psychiatric Pharmacy. He is the associate dean of Student Affairs and a Clinical Professor at the UMKC School of Pharmacy. He received his PharmD from the University of Nebraska College of Pharmacy. Dr. Stoner completed a postdoctoral residency in psychiatric pharmacy practice and administration and a fellowship at Western Missouri Mental Health Center in Kansas City, Missouri.

Miranda Fisher, PhD
Medical Science Liaison

Speaker Steven Stoner, PharmD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Miranda Fisher, Phd. is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Agitation Associated With Alzheimer’s Dementia Disease State Education: Clinical, Humanistic & Economic Burden
2024-05-08 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU Members in Delaware, Maryland, New Jersey, Pennsylvania, and West Virginia.
In this presentation, topics of discussion are:

Clinical burden
Humanistic burden
Economic burden
AAD is associated with substantial patient burden and long-term consequences

Featuring

E. Jeffrey Greenberg, MD
Neurologist at Princeton & Rutgers Neurology, P.A., Co-Founder of Advanced Clinical Institute

More

Dr. Jeffrey Greenberg, a native of Philadelphia, joined Princeton & Rutgers Neurology in 2003. He received his Bachelor’s degree in English from Cornell University and his medical degree from Drexel University, College of Medicine. He completed his Neurology residency at the Albert Einstein College of Medicine in New York, serving as Chief Resident in his final year. He subsequently completed an EMG/Neuromuscular fellowship at Albert Einstein. He is Board Certified in Neurology by the American Board of Psychiatry and Neurology and also Board Certified by the American Associate of Neuromuscular and Electrodiagnostic Medicine.

Dr. Greenberg now focuses his practice on Parkinson’s Disease, Dementia, Multiple Sclerosis, and Neuromuscular Disease. Additionally, he has experience as a Principle Investigator for Alzheimer’s disease clinical trials and remains involved in the field.

Becky Wong, PharmD, MBA
Medical Science Director

Speaker E. Jeffrey Greenberg, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Becky Wong, PharmD, MBA is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Exploring Post-Traumatic Stress Disorder: Treatment Landscape & Unmet Needs
2024-05-02 18:30 - 20:30 (America/New_York) | Manna, 61 W. Franklin St., Centerville, OH, 45459, United States
Home

Events

About This Event

TEST VLE
This is a Live Event for PsychU members in Ohio.
This presentation will examine the current evidence-based guidelines for the diagnosis and treatment of post-traumatic stress disorder (PTSD) and use in the development of individual treatment plans for patients. Additional insights will be reviewed regarding PTSD therapeutic landscape, psychotherapy, and pharmacotherapy, plus limitations and key considerations in the treatment of PTSD.

Venue

Featuring

Taylor Ochalek, PhD
Medical Science Liaison

Speaker Taylor Ochalek, PhD is an employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Virtual Event – Is It MDD Or Bipolar Disorder?
2024-05-01 15:00 - 16:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a National Virtual Event for all PsychU members.
In this presentation, the objectives are to:

Review the prevalence and burden of major depressive disorder (MDD) and bipolar disorder (BD)
Discuss the clinical features of MDD and BD
Address the difficulties in differential diagnosis between MDD and BD

Featuring

Chet Robachinski, MD
Psychiatric Director, Bailey-Boushay House, Seattle, WA; Founding Partner, Associates in Behavioral Health

Simon Kim, PharmD
Medical Science Liaison

Speaker Chet Robachinski, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Simon Kim, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Social Determinants Of Health
2024-05-01 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU members in Delaware, Maryland, New Jersey, Pennsylvania, and West Virginia.
In this presentation, the objectives are to:

Discuss health equity and social determinants of health (SDoH)
What is the relationship to population health?
Discuss how SDoH impacts the economics of the population
Discuss a recent pandemic’s impact and correlation to SDoH
Discuss how payors utilize SDoH data to influence decisions and program investments
Discuss how SDoH can impact value-based payment methods

Featuring

Michael Townsend, MA, LSW/LCSW
Deputy Chief Executive Officer, Gateway Counseling Center

More

Mr. Townsend, is the Deputy Chief Executive Officer at Gateway Counseling Center where he assists the Chief Executive Officer (CEO) with managing and directing the organization towards its primary objectives, serves as a member of the Boardof Directors, as well as the Chair of Audit Committee of the Mental Health Association in New York, and is also the President of GCC Transportation, LLC, which directs transportation services to the transit disabled and medically frail.

Becky Wong, PharmD, MBA
Medical Science Director

Speaker Michael Townsend, MA, LSW/LCSW is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Becky Wong, PharmD, MBA is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Exploring Post-Traumatic Stress Disorder: Treatment Landscape and Unmet Needs Part 2
2024-04-10 12:00 - 12:30 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Current evidence-based guidelines for the diagnosis and treatment of post-traumatic stress disorder (PTSD) are valuable resources and can be used to help develop individual treatment plans for patients. This webinar will examine the current PTSD treatment landscape, including discussions on both psychotherapy and pharmacotherapy. In addition, presenters will review limitations and key considerations in the treatment of PTSD.

Featuring

David Block, MD, MMM, FAPA
Clinical Assistant Professor of Psychiatry, Western University of Health Sciences, Loma Linda University and California University of Health and Medicine; Private Practitioner, Costa Mesa, CA

More

Dr. David Block, a psychiatrist in Orange County, CA, is dual board-certified in psychiatry and addiction medicine and was elected to become a Fellow of the American Psychiatric Association in January 2014. Currently, he is the Clinical Assistant Professor of Psychiatry at the Western University of Health Sciences, Loma Linda University and California University of Health and Medicine, and is a Private Practitioner in Costa Mesa, CA.

Dr. Block has worked extensively in college mental health, managed health care, and community treatment settings with severely and persistently mentally ill individuals. He has extensive clinical experience working with individuals with PTSD, from both his public and private sector work, Additionally, he has written several articles in the psychiatric literature and taught seminars and lectures to students training in the mental health professions.

Madeline Shurtleff, PharmD
Managed Market Liaison

More

Dr. Shurtleff is a clinical pharmacist with experience in managed care and retail pharmacy. She has extensive knowledge in Medicaid and Medicare pharmacy operations and regulatory requirements. Dr. Shurtleff received her Doctor of Pharmacy (PharmD), Business Minor, and Leadership Minor from the University of Rhode Island. She is a licensed pharmacist in Illinois and Arizona.

Speaker David Block, MD, MMM, FAPA is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Madeline Shurtleff is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Agitation Associated With Alzheimer’s Dementia (AAD) In The Long-Term Care (LTC) Setting: An Introduction To The Agitation In Alzheimer’s Screener For Caregivers (AASCTM)
2024-04-03 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This webinar will describe how agitation associated with Alzheimer’s dementia (AAD) can manifest within the long-term care (LTC) setting and the burden that AAD can pose to both residents and caregivers. Presenters will discuss current approaches to recognizing and documenting AAD in the LTC setting, as well as potential challenges faced by nursing home caregivers. The Agitation in Alzheimer’s Screener for Caregivers (AASCTM) will be introduced as a potential tool for the identification and documentation of agitation in LTC residents with Alzheimer’s dementia.

Featuring

Manju Beier, PharmD, BCGP, FASCP
President & Founder, Geriatric Consultant Resources, LLC; Adjunct Associate Professor of Pharmacy at the University of Michigan

More

Dr. Manju T. Beier is President and founder of Geriatric Consultant Resources LLC, a firm established in 1995 to
provide clinical expertise in the field of geriatric pharmacotherapy and clinical pharmacology to geriatrics
professional organizations and health care plans. She has extensive experience targeting complex polypharmacy
issues and addressing medication management in older adults.

Previously, Dr. Beier was Chief Scientific Officer for a molecular diagnostics company based out of Renton, WA.
This position recognized her success as one of the pioneers in the profession of pharmacy for
pharmacogenomics research and education.

She holds an academic appointment as Adjunct Clinical Associate Professor of Pharmacy at the University of
Michigan, Ann Arbor, Michigan since 2000. She is currently a Board-Certified Geriatric Pharmacist (BCGP) until
2028.

Dr. Beier has been serving on the national Epocrates Senior Clinical Board since 2011 as the only pharmacist with
expertise in geriatrics. Her combined expertise in geriatrics, drug-drug and drug-gene interactions make her
uniquely qualified in the domains of personalized medicine, pharmacogenomics, and mitigating polypharmacy.

Dr. Beier received her B.S. Pharmacy and Doctor of Pharmacy degrees from the University of Utah in Salt Lake
City, Utah. She also holds a B.S. degree in Foods and Nutrition from Lady Irwin College, New Delhi, India.

Dr. Beier has given numerous seminars and workshops spanning the last 30 years addressing geriatric
pharmacotherapy, particularly psychopharmacology, pain management, Alzheimer’s Disease, cardiovascular
therapeutics, and the unique medication-related problems of older adults on a local, state, national, and
international level. She has also served on national P&T Committees as an independent member and reviewer.

Dr. Beier is widely published in peer-reviewed journals. She currently serves on the editorial advisory board of
several journals related to geriatrics and aging including Journal of the American Medical Directors Association
(JAMDA), and The Senior Care Pharmacist.

Dr. Beier is actively involved with the American Society of Consultant Pharmacists (ASCP) including serving two
terms on the Board of Directors. She recently completed her tenure as chair of Deprescribing Task Force for
ASCP (2018-2022) and was the chair/lead developer of Choosing Wisely Statements published online May 2021
and June 2022.

Dr. Beier was elected chair of the ASCP Foundation 2018-2020. She also co-chaired the ASCP Field Guide to
Reduce Medication Burden During COVID-19.

She belongs to several other national professional associations including American Medical Directors
Association (AMDA), and College of Psychiatric and Neurologic Pharmacists (CPNP).

Dr. Beier served as an expert panel national member for the 2003 Beers Criteria for Potentially Inappropriate
Drugs in the Elderly.

She is the recipient of several national pharmacy awards including being the 2006 recipient of the prestigious
George F. Archambault Award conferred by ASCP which is the Society’s highest honor. In 2012, she received the
Richard S. Berman Service Award for outstanding service and dedication to ASCP.

In November 2020, she was recognized as the recipient of the Women’s Spotlight Award by ASCP that recognizes
a female pharmacist for her outstanding contributions to senior care pharmacy and the mission of ASCP.

Jennifer Simmoneau, PhD (OPDC)
Senior Long-Term Care Medical Science Liaison, Medical Affairs

Speaker Manju Beier is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Jennifer Simmoneau, PhD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Strategies To Optimize Patient Outcomes In Bipolar-I Disorder: Role Of Long-Acting Injectable Antipsychotics
2024-04-02 18:00 - 21:00 (America/New_York) | Sullivan’s Steakhouse, 3316 E 86th St, Indianapolis, IN, 46240, United States
Home

Events

About This Event

TEST VLE
In this presentation, the objectives are to:

Understand the impact of mood episode recurrence in bipolar I disorder on patient functioning and clinical outcomes
Discuss risk factors for mood episode recurrence, including nonadherence, in patients with bipolar I disorder
Review management strategies, including long-acting injectable antipsychotics (LAIs), to optimize patient outcomes in bipolar I disorder

Venue

Featuring

Areef Kassam, MD, MPA
Community Health Network Psychiatry Residency Associate Program Director

More

Dr. Areef Kassam has served as the Associate Program Director for the Psychiatry Residency Training Program at Community Health Network since 2020. Additionally, he works clinically at Community Fairbanks Behavioral Health Gallahue Community Support Services clinic where he supervises teams providing holistic, foundational care for individuals struggling with Schizophrenia and Bipolar Disorder through community-based programming and services. Dr. Kassam completed his B.S. in Biology from IUPUI as well as his Masters in Public Affairs with a concentration in Health Services Administration at IU. He graduated from medical school from the Medical University of the Americas in 2014, before joining Community Health Network’s inaugural class for its new psychiatry program in 2016. Dr. Kassam is passionate about education, especially interdisciplinary learning and integration. He is Clinical Faculty at Marian University Medical School, as well as clinical preceptor through Purdue University and Butler University for their PMHNP and Physician’s Assistant programs. Dr. Kassam sits on several local and national committees and taskforces engaged in promoting psychiatric education, workforce enhancement, as well as fostering growth with justice, equity, diversity, and inclusion.

Alex Matushek, PharmD, MBA
Medical Science Liaison

Speaker Areef Kassam, MD, MPA is paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Moderator Alex Matushek, PharmD, MBA is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Comorbidities In Patients Living With Bipolar I Disorder
2024-03-28 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Lifetime comorbidity rates in bipolar disorder are ~90%, and nearly half of these patients are treated for a minimum of three1. During this webinar, Otsuka Sr. MSL Dr. Michael Aldape will be talking with Dr. Joseph Goldberg who will guide us on a lively discussion addressing the complexities of psychiatric comorbidities associated with bipolar I disorder. This moderated session will explore common comorbidities, treatment options and the current guidelines for managing comorbid bipolar I patients.

1. Altinbas, K. Treatment of Comorbid Psychiatric Disorders with Bipolar Disorder. Noro Psikiyatr Ars. 2021 Sep 20;58 (Suppl 1): S41-S46.

Featuring

Joseph Goldberg, MD
Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai

More

Joseph F. Goldberg, MD is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. He attended college at the University of Chicago, graduate school in neuroscience at the University of Illinois, and medical school at Northwestern University. He completed his residency and chief residency in psychiatry, and fellowship in psychopharmacology, at the Payne Whitney Clinic, New York Presbyterian Hospital, where he later served on the faculty and was site Principal Investigator at Weill-Cornell Medical Center for the NIMH STEP-BD program. He has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology, most recently “Managing the Side Effects of Psychotropic Medications, 2nd edition” published in 2019 by American Psychiatric Publishing, and the forthcoming “Practical Psychopharmacology” by Cambridge University Press. He serves on the Board of Directors for the American Society of Clinical Psychopharmacology and is on the editorial boards for a number of peer-reviewed journals. His research has been awarded funding from NARSAD, NIMH, the Stanley Foundation, and the American Foundation for Suicide Prevention. Dr. Goldberg is a Distinguished Fellow of the American Psychiatric Association and has been listed for many years in Best Doctors in America and Castle Connolly’s “America’s Top Doctors.”

Michael Aldape, PhD
Senior Medical Science Liaison

Speaker Joseph F Goldberg, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Michael Aldape, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Exploring Post-Traumatic Stress Disorder: Treatment Landscape & Unmet Needs
2024-02-28 12:00 - 12:30 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Current evidence-based guidelines for the diagnosis and treatment of post-traumatic stress disorder (PTSD) are valuable resources and can be used to help develop individual treatment plans for patients. This webinar will examine the current PTSD treatment landscape, including discussions on both psychotherapy and pharmacotherapy. In addition, presenters will review limitations and key considerations in the treatment of PTSD.

Featuring

David Block, MD, MMM, FAPA
Clinical Assistant Professor of Psychiatry, Western University of Health Sciences, Loma Linda University and California University of Health and Medicine; Private Practitioner, Costa Mesa, CA

More

Dr. David Block, a psychiatrist in Orange County, CA, is dual board-certified in psychiatry and addiction medicine and was elected to become a Fellow of the American Psychiatric Association in January 2014. Currently, he is the Clinical Assistant Professor of Psychiatry at the Western University of Health Sciences, Loma Linda University and California University of Health and Medicine, and is a Private Practitioner in Costa Mesa, CA.

Dr. Block has worked extensively in college mental health, managed health care, and community treatment settings with severely and persistently mentally ill individuals. He has extensive clinical experience working with individuals with PTSD, from both his public and private sector work, Additionally, he has written several articles in the psychiatric literature and taught seminars and lectures to students training in the mental health professions.

Madeline Shurtleff, PharmD
Managed Market Liaison

More

Dr. Shurtleff is a clinical pharmacist with experience in managed care and retail pharmacy. She has extensive knowledge in Medicaid and Medicare pharmacy operations and regulatory requirements. Dr. Shurtleff received her Doctor of Pharmacy (PharmD), Business Minor, and Leadership Minor from the University of Rhode Island. She is a licensed pharmacist in Illinois and Arizona.

David Block, MD, MMM, FAPA is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.Madeline Shurtleff, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Let’s Face It, The Current Treatment Options For MDD Are Not Enough: Learn About Cognitive Emotional Training
2024-02-22 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
During an expert interview, Otsuka Sr. MSL, Dr. Mark Tacelosky will be talking with Dr. Brian Iacoviello who will guide us through Cognitive Emotional Training for the treatment of major depressive disorder (MDD). The objectives of this activity include providing the rationale for the role of cognitive-emotional training, exploring the steps for developing a cognitive-emotional training intervention for the treatment of MDD, reviewing the options for the digital delivery of cognitive emotional training, and discussing the possibilities for future research and applications.

Featuring

Brian Iacoviello, PhD
Assistant Professor, Icahn School of Medicine at Mount Sinai New York, NY

More

Dr. Iacoviello is a clinical psychologist and assistant professor at the Icahn School of Medicine at Mount Sinai. He earned his Masters and PhD in clinical psychology from Temple University in PA. Dr Iacoviello specializes in treating mood and anxiety disorders, using cognitive behavioral therapy, dialectical behavior therapy, acceptance and commitment therapy and motivational interviewing. His research delves into understanding fundamental cognitive behavioral patterns associated with depression, bipolar disorder, and anxiety disorders to search for novel treatments

Mark Tacelosky, PharmD
Senior Medical Science Liaison

Brian Iacoviello, PhD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Mark Tacelosky, PharmD is an employee for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Unmet Needs In Agitation Associated With Alzheimer's Dementia (AAD)
2024-02-21 18:30 - 20:30 (America/New_York) | Lusardi’s, 1885 Palmer Ave, Larchmont, NY, 10538, United States
Home

Events

About This Event

TEST VLE
This evidence-based review highlights important aspects of agitation associated with Alzheimer’s Dementia (AAD) for better understanding of the prevalence and challenges in diagnosis and explore the potential pathobiological correlations in AAD. Describes the clinical and humanistic burden and discusses current guidelines for nonpharmacological and pharmacological treatments of this complex and prominent complication of an already devastating disease. It underlines unmet needs for FDA-approved pharmaceutical treatments for agitation to improve care and quality of life for patients suffering from AAD.

Venue

Featuring

George Alexopoulos, MD
DeWitt Wallace Distinguished Scholar, Founding Director, Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine

Jehan Marino, PharmD, BCPP
Medical Science Director

Erika Modh, PharmD, BCPS
Medical Science Liaison

Speaker George Alexopoulos, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speakers Jehan Marino, PharmD, BCPP and Erika Modh, PharmD, BCPS are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Virtual Event - Inadequately Treated Major Depressive Disorder (MDD)
2024-02-20 12:30 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU members in Arkansas, Indiana, Kentucky, Louisiana, Mississippi, Texas, and West Virginia.
In this presentation, the objectives are to:

Describe the prevalence of depression in the US
Highlight the burden of MDD
Identify inadequately treated MDD and understand how it impacts patients
Understand which patients are at risk for inadequately treated MDD
Explain MDD treatment strategies

Featuring

Lindsey Wright, PharmD
Medical Science Liaison

Amaka Onyereri, PharmD, BCPS
Medical Science Liaison

More

Amaka Onyereri received her bachelor’s degree in general science and Doctor of Pharmacy degree from Oregon State University/Oregon Health Sciences University. Her passion for patient care led her to practice clinically as a community pharmacist where she served patients for close to 20 years in different capacities as a staff pharmacist, pharmacy manager and pharmacy clinical services manager.
As a Pharmacy Clinical Services Manager, Amaka spearheaded various clinical and patient care initiatives such as immunizations, medication therapy management, point of care testing, and most recently a long-acting injectables pilot for antipsychotics.

Speakers Lindsey Wright, PharmD and Amaka Onyereri, PharmD, BCPS are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Born This Way? The Role Of Early Life Stress In Adult Mental Illness
2024-02-01 15:00 - 16:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

https://forms.office.com/r/XmfW5c5MvQ

About This Event

TEST VLE
In this presentation, the objectives are to:

Recognize early life adversity as a risk factor for the development of psychiatric illness across diagnostic boundaries
Characterize biological and neurobiological mechanisms that implicate childhood trauma and stress in adult mental illness
Understand the importance of assessing early life events in the clinical setting

Featuring

Chet Robachinski, MD
Psychiatric Director, Bailey-Boushay House, Seattle, WA; Founding Partner, Associates in Behavioral Health

Simon Kim, PharmD
Medical Science Liaison

Speaker Chet Robachinski, MD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Simon Kim, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Conversations Matter: The Importance Of Effective Communication Between Healthcare Providers & Care Partners Of Individuals Living With Agitation In Alzheimer’s Dementia (AAD)
2023-12-13 15:00 - 16:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Care partners play an integral role in the detection and assessment of agitation symptoms in patients with Alzheimer’s dementia1 and are often the first to communicate these behaviors to healthcare providers (HCPs)2,3. Early identification, management and treatment of AAD has been shown to improve patient outcomes and reduce caregiver burden4,5, highlighting the importance of a strong therapeutic alliance between care partners and HCPs. In this webinar, geriatric psychiatrist, Dr. Marc Agronin, and care partner, Carrie Shaw, share their unique but complimentary perspectives on identifying and responding to agitation and navigating the shared decision-making process. Our speakers will discuss best practices for how to effectively prepare for and communicate during an appointment and what tools and resources are available for care partners. One such tool they review is the AASC™, a brief screening tool based on the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders6, which was designed to assist caregivers in recognizing AAD.

Click here to register for the 12:00 pm EST broadcast

References:

Stella F, et al. Int J Geriatr Psychiatry. 2015;30(12):1230-1237
Lindeza P, et al. BMJ Support Palliat Care. 2020; bmjspcare-2020-002242.
Gallego-Alberto L, et al. Clin Gerontol. 2022;45(5):1295-1303.
Hoe J, et al. BJPsych Open. 2017;3(1):34-40.
Janzen S, et al. Am J Alzheimers Dis Other Demen. 2013;28(5):524-532
Sano M, et al. International Psychogeriatrics 2023 :1-13. doi10.1017/S1041610222001041

Featuring

Marc E. Agronin, MD
Agitation Section Advisor; President of the American Association for Geriatric Psychiatry (AAGP); Senior Vice President for Behavioral Health and Chief Medical Office for the Memory and Research Center at MIND Institute; Affiliate Associate Professor of Psychiatry and Neurology at the University of Miami Miller School of Medicine

Carrie Shaw, MD
CEO & Founder of Embodied Labs

Miranda Fisher, PhD
Medical Science Liaison

Marc Agronin and Carrie Shaw are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Miranda Fisher, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Conversations Matter: The Importance Of Effective Communication Between Healthcare Providers & Care Partners Of Individuals Living With Agitation In Alzheimer's Dementia (AAD)
2023-12-13 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Care partners play an integral role in the detection and assessment of agitation symptoms in patients with Alzheimer’s dementia1 and are often the first to communicate these behaviors to healthcare providers (HCPs)2,3. Early identification, management and treatment of AAD has been shown to improve patient outcomes and reduce caregiver burden4,5, highlighting the importance of a strong therapeutic alliance between care partners and HCPs. In this webinar, geriatric psychiatrist, Dr. Marc Agronin, and care partner, Carrie Shaw, share their unique but complimentary perspectives on identifying and responding to agitation and navigating the shared decision-making process. Our speakers will discuss best practices for how to effectively prepare for and communicate during an appointment and what tools and resources are available for care partners. One such tool they review is the AASC™, a brief screening tool based on the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders6, which was designed to assist caregivers in recognizing AAD.

Click here to register for the 3:00 pm EST broadcast

References:

Stella F, et al. Int J Geriatr Psychiatry. 2015;30(12):1230-1237
Lindeza P, et al. BMJ Support Palliat Care. 2020; bmjspcare-2020-002242.
Gallego-Alberto L, et al. Clin Gerontol. 2022;45(5):1295-1303.
Hoe J, et al. BJPsych Open. 2017;3(1):34-40.
Janzen S, et al. Am J Alzheimers Dis Other Demen. 2013;28(5):524-532
Sano M, et al. International Psychogeriatrics 2023 :1-13. doi10.1017/S1041610222001041

Featuring

Marc E. Agronin, MD
Agitation Section Advisor; President of the American Association for Geriatric Psychiatry (AAGP); Senior Vice President for Behavioral Health and Chief Medical Office for the Memory and Research Center at MIND Institute; Affiliate Associate Professor of Psychiatry and Neurology at the University of Miami Miller School of Medicine

Carrie Shaw, MD
CEO & Founder of Embodied Labs

Miranda Fisher, PhD
Medical Science Liaison

Marc Agronin and Carrie Shaw are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Miranda Fisher, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…
